Genentech, Inc.

Ventana Medical Systems, Inc.

Foundation Medicine, Inc.

Spring Bioscience Corporation

F. Hoffmann-la Roche Ag

Marcin Kowanetz

Hartmut Koeppen

Priti Hegde

Zhiming Liao

Yifei Zhu

Patrick C Roche

Bharathi Vennapusa

Zachary Boyd

Roman Yelensky

Philip James Stephens

Sanjeev Mariathasan

Garrett Michael Frampton

James Xin Sun

Richard Bourgon

David Fabrizio

David Shames

Gregg Fine

Daniel Shin-Yu Chen

Edward Kadel

Kimberly Walter

Wei Zou

Caitlin F Connelly

Zachary R Chalmers

Garrett Michaell Frampton

Priti Hedge

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

Therapeutic and diagnostic methods for cancer

The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.

Anti-PD-L1 antibodies and diagnostic uses thereof

Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.

Biomarkers and methods of treating PD-1 and PD-L1 related conditions

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

This invention provides methods for the treatment of cancer in subjects having medium or low methylation level in the PD-L1 promoter region. Also provided are related kits and articles of manufacture.

PD-L1 promoter methylation in cancer

Growing community of inventors

South San Francisco, CA, United States of America

Marcin Kowanetz